The trial is testing the product as a potential treatment for synovial sarcoma, a cancer that appears in soft tissue, and SMARCB1-deleted tumors. Foghorn halted the trial after a “grade 4 QTc prolongation event in a synovial sarcoma patient at the second highest dose,” meaning the cancer patient’s heartbeat slowed or took longer than normal to contract and relax.
“[The] FDA placed the study on partial clinical hold in the United States, while allowing patients currently enrolled and benefiting from therapy to continue dosing and to remain on FHD-609,” Foghorn said, adding it “is not at this time planning to pursue a dose expansion study independently.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
